Patents Assigned to Tempus Labs, Inc.
-
Patent number: 11875903Abstract: A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.Type: GrantFiled: August 30, 2021Date of Patent: January 16, 2024Assignee: Tempus Labs, Inc.Inventors: Jeff Schaeffer, Hailey Lefkofsky, Carin Fishel Queen, Abigail Lammers
-
Patent number: 11869668Abstract: A method and system for predicting the likelihood that a patient will suffer from a cardiac event is provided. The method includes receiving electrocardiogram data associated with the patient, providing at least a portion of the electrocardiogram data to a trained model, receiving a risk score indicative of the likelihood the patient will suffer from the cardiac event within a predetermined period of time from when the electrocardiogram data was generated, and outputting the risk score to at least one of a memory or a display for viewing by a medical practitioner or healthcare administrator. The system includes at least one processor executing instructions to carry out the steps of the method.Type: GrantFiled: May 31, 2022Date of Patent: January 9, 2024Assignees: Tempus Labs, Inc., Geisinger ClinicInventors: Arun Nemani, Greg Lee, Steve Steinhubl, Alvaro Ulloa-Cerna
-
Patent number: 11848107Abstract: Systems and methods are provided for predicting metastasis of a cancer in a subject. A plurality of data elements for the subject's cancer is obtained, including sequence features comprising relative abundance values for gene expression in a cancer biopsy of the subject, optional personal characteristics about the subject, and optional clinical features related to the stage, histopathological grade, diagnosis, symptom, comorbidity, and/or treatment of the cancer in the subject, and/or a temporal element associated therewith. One or more models are applied to the plurality of data elements, determining one or more indications of whether the cancer will metastasize. A clinical report comprising the one or more indications is generated.Type: GrantFiled: December 21, 2021Date of Patent: December 19, 2023Assignee: Tempus Labs, Inc.Inventors: Ashraf Hafez, Martin Christian Stumpe, Nike Beaubier, Daniel Neems, Caroline Epstein, Adrian William George Lange
-
Patent number: 11769572Abstract: A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.Type: GrantFiled: December 31, 2020Date of Patent: September 26, 2023Assignee: Tempus Labs, Inc.Inventors: Hailey Lefkofsky, Ashraf Hafez, Julian Habib, Carin Fishel Queen, Caroline Epstein
-
Patent number: 11756688Abstract: A method for determining cardiology disease risk from electrocardiogram trace data and clinical data includes receiving electrocardiogram trace data associated with a patient, receiving the patient's clinical data, providing both sets of data to a trained machine learning composite model that is trained to evaluate the data with respect to each disease of a set of cardiology diseases including three or more of cardiac amyloidosis, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, abnormal reduced ejection fraction, or abnormal interventricular septal thickness, generating, by the model and based on the evaluation, a composite risk score reflecting a likelihood of the patient being diagnosed with one or more of the cardiology diseases within a predetermined period of time from when the electrocardiogram trace data was generated, and outputting the composite risk score to at least one of a memory or a display.Type: GrantFiled: May 31, 2022Date of Patent: September 12, 2023Assignees: Tempus Labs, Inc., Geisinger ClinicInventors: Alvaro E. Ulloa-Cerna, Noah Zimmerman, Greg Lee, Christopher M. Haggerty, Brandon K. Fornwalt, Ruijun Chen, John Pfeifer, Christopher Good
-
Patent number: 11715467Abstract: A method and system of audibly broadcasting responses to a user based on user queries about a specific patient report, the method comprising receiving an audible query from the user to a microphone coupled to a collaboration device, identifying at least one intent associated with the audible query, identifying at least one data operation associated with the at least one intent, associating each of the at least one data operations with a first set of data presented on the report, executing each of the at least one data operations on a second set of data to generate response data, generating an audible response file associated with the response data and providing the audible response file for broadcasting via a speaker coupled to the collaboration device.Type: GrantFiled: April 17, 2020Date of Patent: August 1, 2023Assignee: Tempus Labs, Inc.Inventors: Eric Lefkofsky, Jonathan Ozeran
-
Patent number: 11715565Abstract: Systems and methods are provided for implementing a tool for evaluating an effect on an event, such as a medication or treatment, on a subject's condition, using a propensity model that identifies matched treatment and control cohorts within a base population of subjects. A propensity value threshold, which can be obtained based on user input, can be used to adjust the selection of subjects for treatment and control cohorts. The tool allows analyzing features of the subjects in the treatment and control groups, and further allows for evaluation and comparison of survival objectives of subjects in the treatment and control groups.Type: GrantFiled: November 8, 2019Date of Patent: August 1, 2023Assignee: Tempus Labs, Inc.Inventors: Ashraf Hafez, Caroline Epstein
-
Patent number: 11705226Abstract: A method and system for storing user application programs and micro-service programs, for each of multiple patients that have cancerous cells and receive treatment, includes obtaining clinical records data in original forms, storing it in a semi-structured first database, generating sequencing data for the patient's cancerous and normal cells using a next generation genomic sequencer, storing the sequencing data in the first database, shaping at least some of the first database data to generate system structured data optimized for searching and including clinical record data, storing the structured data in a second database, for each user application program, selecting an application-specific subset of data from the second database and storing it in a structure optimized for application program interfacing in a third database, wherein an orchestration manager operatively connected to one or more micro-service programs receives status messages and initiates a respective micro-service program when program prereType: GrantFiled: October 18, 2019Date of Patent: July 18, 2023Assignee: Tempus Labs, Inc.Inventors: Shane Colley, Isaiah Simpson, Brian Reuter, Robert Tell, Hailey Lefkofsky, Hunter Lane, Kevin White, Nike Beaubier, Stephen Bush, Aly Khan, Denise Lau, Kaanan Shah, Eric Lefkofsky
-
Patent number: 11699507Abstract: A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.Type: GrantFiled: July 22, 2021Date of Patent: July 11, 2023Assignee: Tempus Labs, Inc.Inventors: Hailey Lefkofsky, Ashraf Hafez, Julian Habib, Carin Fishel, Caroline Epstein
-
Patent number: 11682481Abstract: A system for personalized depression disorder treatment is disclosed herein. The system includes a server configured to communicate with existing healthcare resources and to receive patient data corresponding to a patient, the server including an analytics module. The system further includes a first database configured to store empirical patient outcomes, and further configured to communicate with the analytics module. Additionally, the system includes a user device having a graphical user interface (GUI) configured to communicate with the server and to display at least one output generated by the analytics module. The analytics module is configured to determine at least one of a personalized depression treatment and a personalized depression state prediction based on the empirical patient outcomes and the patient data.Type: GrantFiled: March 22, 2021Date of Patent: June 20, 2023Assignee: Tempus Labs, Inc.Inventors: Hailey B. Lefkofsky, Christopher N. Vlangos
-
Patent number: 11657921Abstract: A method and system for predicting the likelihood that a patient will suffer from a cardiac event is provided. The method includes receiving electrocardiogram data associated with the patient, providing at least a portion of the electrocardiogram data to a trained model, receiving a risk score indicative of the likelihood the patient will suffer from the cardiac event within a predetermined period of time from when the electrocardiogram data was generated, and outputting the risk score to at least one of a memory or a display for viewing by a medical practitioner or healthcare administrator. The system includes at least one processor executing instructions to carry out the steps of the method.Type: GrantFiled: May 31, 2022Date of Patent: May 23, 2023Assignees: Tempus Labs, Inc., Geisinger ClinicInventors: Noah Zimmerman, Brandon Fornwalt, John Pfeifer, Ruijun Chen, Arun Nemani, Greg Lee, Steve Steinhubl, Christopher Haggerty, Sushravya Raghunath, Alvaro Ulloa-Cerna, Linyuan Jing, Thomas Morland
-
Patent number: 11640859Abstract: A method and system for conducting genomic sequencing, the method comprising storing a set of user application programs wherein each of the programs requires an application specific subset of data, for each of a plurality of patients that have cancerous cells and that receive cancer treatment, obtaining clinical records data in original forms including cancer state information, treatment types and treatment efficacy information, storing the clinical records data in a semi-structured first database, for each patient, using a genomic sequencer to generate genomic sequencing data for the patient's cancerous cells and normal cells, storing the sequencing data in the first database, shaping at least a subset of the first database data to generate system structured data including clinical record data and sequencing data wherein the system structured data is optimized for searching, storing the system structured data in a second database, for each user application program, selecting the application specific subset oType: GrantFiled: October 17, 2019Date of Patent: May 2, 2023Assignee: Tempus Labs, Inc.Inventors: Shane Colley, Isaiah Simpson, Brian Reuter, Robert Tell, Hailey Lefkofsky, Hunter Lane, Kevin White, Nike Beaubier, Stephen Bush, Aly Khan, Denise Lau, Kaanan Shah, Eric Lefkofsky
-
Patent number: 11629385Abstract: Provided herein are novel organoid culture media, organoid culture systems, and methods of culturing tumor organoids using the subject organoid culture media. Also provided herein are tumor organoids developed using such organoid culture systems, methods for assessing the clonal diversity of the tumor organoids, and methods for using such tumor organoids, for example, for tumor modelling and drug development applications. In particular embodiments, the tumor organoid culture media provided herein is substantially free of R-spondins (e.g., R-spondin1).Type: GrantFiled: November 22, 2019Date of Patent: April 18, 2023Assignee: Tempus Labs, Inc.Inventors: Ameen Salahudeen, Verónica Sánchez Freire, Brandon L. Mapes
-
Patent number: 11613783Abstract: The present disclosure provides methods, systems, compositions, and kits for the high-throughput detection of multi-molecule biomarkers in a biological sample. The disclosed methods, systems, compositions, and kits utilize antibody-oligonucleotide tags to detect two or more molecules that are in close proximity.Type: GrantFiled: December 30, 2021Date of Patent: March 28, 2023Assignee: Tempus Labs, Inc.Inventor: Timothy Rand
-
Patent number: 11594222Abstract: A method and system of audibly broadcasting responses to a user based on user queries about a specific patient molecular report, the method comprising receiving an audible query from the user to a microphone coupled to a collaboration device, identifying at least one intent associated with the audible query, identifying at least one data operation associated with the at least one intent, associating each of the at least one data operations with a first set of data presented on the molecular report, executing each of the at least one data operations on a second set of data to generate response data, generating an audible response file associated with the response data and providing the audible response file for broadcasting via a speaker coupled to the collaboration device.Type: GrantFiled: July 28, 2021Date of Patent: February 28, 2023Assignee: Tempus Labs, Inc.Inventors: Eric Lefkofsky, Jonathan Ozeran
-
Patent number: 11561178Abstract: The disclosure provides a method of generating an artificial fluorescent image of cells is provided.Type: GrantFiled: April 20, 2021Date of Patent: January 24, 2023Assignee: Tempus Labs, Inc.Inventors: Madhavi Kannan, Brian Larsen, Aly A. Khan, Ameen Salahudeen
-
Patent number: 11532397Abstract: A system, method, and mobile device application are configured to capture, with a mobile device, a document such as a next generation sequencing (NGS) report that includes NGS medical information about a genetically sequenced patient. The method includes receiving, from a mobile device, an image of a medical document comprising NGS medical information of the patient, extracting a first region from the image, extracting NGS medical information of the patient from the first region into a structured dataset, the extracted NGS medical information including at least one RNA expression, correlating a portion of the extracted NGS medical information that includes the at least one RNA expression with summarized medical information from a cohort of patients similar to the patient, and generating, for display on the mobile device, a clinical decision support report comprising the summarized medical information.Type: GrantFiled: January 25, 2021Date of Patent: December 20, 2022Assignee: Tempus Labs, Inc.Inventors: Michael Ryan Lucas, Jonathan Ozeran, Jason L. Taylor, Louis E. Fernandes, Daniel Neems, Hunter Lane, Eric Lefkofsky
-
Patent number: 11527323Abstract: Systems and methods are provided for identifying a diagnosis of a cancer condition for a somatic tumor specimen of a subject. The method receives sequencing information comprising analysis of a plurality of nucleic acids derived from the somatic tumor specimen. The method identifies a plurality of features from the sequencing information, including two or more of RNA, DNA, RNA splicing, viral, and copy number features. The method provides a first subset of features and a second subset of features from the identified plurality of features as inputs to a first classifier and a second classifier, respectively. The method generates, from two or more classifiers, two or more predictions of cancer condition based at least in part on the identified plurality of features. The method combines, at a final classifier, the two or more predictions to identify the diagnosis of the cancer condition for the somatic tumor specimen of the subject.Type: GrantFiled: May 12, 2020Date of Patent: December 13, 2022Assignee: Tempus Labs, Inc.Inventors: Jackson Michuda, Kyle Ashley Beauchamp, Joshuah Kapilivsky, Calvin McCarter, Nike Beaubier, Martin Christian Stumpe, Catherine Igartua, Joshua S K Bell, Timothy Taxter, Raphael Pelossof
-
Patent number: 11521710Abstract: A system and method that receive a distance matrix for multiple patients and a patient of interest, assign a radial distance value between the patient of interest and the other patients based on the distance matrix value for each of the multiple patients, generate an angular distance value between the multiple patients based at least in part on a measure of similarity between each patient, and minimize a cost function based at least in part on the angular distance value between each patient and each other patient. Minimizing the cost function may include calculating a patient contribution to the cost function for a plurality of angular distance values and selecting the angular distance value with the smallest patient contribution. The processor also may be configured to generate and display a radar plot based on the assigned radial distance value and generated angular distance value of each patient.Type: GrantFiled: October 31, 2019Date of Patent: December 6, 2022Assignee: Tempus Labs, Inc.Inventor: Mathew Barber
-
Patent number: 11475981Abstract: Methods, systems, and software are provided for validating a somatic sequence variant in a subject having a cancer condition. Sequence reads are obtained from sequencing cell-free DNA fragments in a liquid biopsy sample of the subject. Sequence reads are aligned to a reference sequence. A variant allele fragment count and locus fragment count are identified for a candidate variant that maps to a locus in the reference sequence. The variant allele fragment count is compared against a dynamic variant count threshold for the locus. The threshold is based on a pre-test odds of a positive variant call for the locus, based on the prevalence of variants in a genomic region including the locus in a cohort of subjects having the cancer condition. The somatic sequence variant in the subject is validated, or rejected, when the variant allele fragment count for the candidate variant satisfies, or does not satisfy, the threshold.Type: GrantFiled: February 18, 2021Date of Patent: October 18, 2022Assignee: Tempus Labs, Inc.Inventors: Robert Tell, Wei Zhu, Justin David Finkle, Christine Lo, Terri M. Driessen